5 Amendments of Dagmar ROTH-BEHRENDT related to 2011/0429(COD)
Amendment 51 #
Proposal for a directive
Recital 8 a (new)
Recital 8 a (new)
(8a) The pollution of waters and soils with pharmaceutical residues is an emerging environmental problem. Current evaluation and control of the risk to or via the aquatic environment of medicinal products does not provide adequate attention to Union environmental objectives. An ongoing Commission study on the risks of environmental effects of medicinal products aims therefore at providing an analysis of the relevance of the current legislative framework to, and its effectiveness at, protecting the environment and human health via the aquatic environment, and finally an identification of possible measures to better address the problem.
Amendment 52 #
Proposal for a directive
Recital 8 b (new)
Recital 8 b (new)
(8b) This proposal aims at ensuring a better quality of water for public health and biodiversity reasons. The pharmaceutical substances which have been prioritised are identified due to a significant risk that they pose to or via the aquatic environment at Union level and not due to a risk on public health via human consumption.
Amendment 53 #
Proposal for a directive
Recital 8 c (new)
Recital 8 c (new)
(8c) Control measures which may be taken by the Member States shall take into account the therapeutic importance of the pharmaceutical substances and be in accordance with Regulation (EU) No 1235/2010 of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance of medicinal products for human use, Regulation (EC) No 726/2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency, and Regulation (EC) No 1394/2007 on advanced therapy medicinal products1 and Directive 2010/84/EU of the European Parliament and of the Council of 15 December 2010 amending, as regards pharmacovigilance, Directive 2001/83/EC on the Community code relating to medicinal products for human use2. These measures may include take- back and labelling schemes for unused pharmaceuticals. ______________ 1 OJ L 348, 31.12.2010, p. 1 2 OJ L 348, 31.12.2010, p. 74
Amendment 91 #
Proposal for a directive
Article 2 – point 3 a (new)
Article 2 – point 3 a (new)
Directive 2008/105/EC
Article 7 a (new)
Article 7 a (new)
Amendment 222 #
Proposal for a directive
Annex II a (new)
Annex II a (new)
Directive 2008/105/EC
Annex II (new)
Annex II (new)